Year: 2023
Type: conference-abstract
Abstract: Decreased aortic compliance is a major risk factor for the development of cardiovascular disease. Aortic compliance can be measured non-invasively by pulse wave velocity. Decreased aortic compliance is marked by increased pulse wave velocity. Clinically, increased pulse wave velocity is associated with increased mortality. As we age, aortic compliance decreases due to loss of elastic extracellular matrix (ECM) components and accumulation of non-elastic ECM components. Vascular smooth muscle cells are the predominant cell type in the aortic wall. VSMCs exist in mechanical balance with the ECM. In response to these ECM changes, VSMCs generate increased actomyosin derived force and further decrease aortic compliance. However, our understanding of the VSMC response to these ECM changes remains poor. Using hydrogels of physiological and pathological aortic stiffness, we have established an in vitro screening assay to identify novel regulators of VSMCs response to increased ECM stiffness. In response to angiotensin II stimulation, VSMCs contract on pliable hydrogels. In contrast, VSMC hypertrophy is induced on rigid hydrogels. Protein acetylation regulates several key processes that determine VSMC function, including heterochromatin and microtubule organisation. We therefore hypothesised that protein deacetylation may be a component of the VSMC ECM rigidity response. We screen a panel of commercially available protein deacetylase inhibitors for their ability to block the VSMC hypertrophic response. Quiescent VSMCs were pre-treated with either a HDAC3 (RGFP966), HDAC6 (Tubastatin) or Sirtuin 1 (EX527) inhibitor prior to angiotensin II stimulation. Analysis revealed that HDAC3 inhibition blocked increased VSMC area on rigid hydrogels specifically; HDAC6 inhibition decreased VSMC area on both pliable and rigid hydrogels; Sirtuin 1 inhibition had no effect on VSMC area at either stiffness. The HDAC3 and HDAC6 inhibitor responses were further analysed by confocal microscopy. Analysis revealed that HDAC3 inhibitor pre-treatment reduced VSMC volume specifically on rigid hydrogels. In contrast, VSMC volume was unaffected by HDAC6 inhibitor treatment on both pliable and rigid hydrogels. Further analysis revealed that nuclear volume was decreased by HDAC3 inhibition on rigid hydrogels, whereas HDAC6 inhibition resulted in decreased nuclear volume on pliable hydrogels. Because of these changes in nuclear morphology, we next predicted that DNA damage would be affected. To test this possibility, we performed immunofluorescence microscopy to observe yH2AX levels in angiotensin II stimulated VSMCs on pliable and rigid hydrogels. Levels of yH2AX significantly decreased on rigid hydrogels treated with HDAC3i back to levels on Angiotensin II stimulated pliable hydrogel. Tubastatin, however, caused an increase in yH2AX marking an increase in DNA damage in VMSCs on pliable hydrogels. Our studies show that HDAC3 inhibitors may be beneficial to increase aortic compliance as opposed to HDAC6 inhibitors (currently being trialled as a cancer therapy) which may be harmful for VSMCs. Further studies are needed on other classes of HDAC to understand the effects on aortic compliance. Conflict of Interest No conflict of Interest
Source: Heart
Authors: Reesha Solanki, Derek Warren, Robert Johnson
Institution: University of East Anglia
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4384567904
